Drug Trial Radar · NCT07021794
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Nancy KlimasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Florida Department of Health
- First posted
- Jun 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
Conditions
- Post-COVID / Long-COVID
Interventions
PlaceboDrug
A single dose of placebo (saline) indistinguishable from the active drug in appearance
SipavibartBiological
A single intramuscular dose of Sipavibart, 300 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-Reported Outcomes Measurement Information System-29Time frame: 12 weeks
- Review of Treatment Related Adverse EventsTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nova Southeastern University
Fort Lauderdale, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.